ARS Pharmaceuticals, Inc. (SPRY) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -215.43M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-215.43M | (m) |
| 2026-03-31 | (m) | $-197.98M | (m) |
| 2025-12-31 | (m) | $-171.30M | (m) |
| 2025-09-30 | (m) | $-80.04M | (m) |
| 2025-06-30 | (m) | $-48.02M | (m) |
| 2025-03-31 | (m) | $-15.65M | (m) |
| 2024-12-31 | (m) | $8.00M | (m) |
| 2024-09-30 | (m) | $-49.10M | (m) |
| 2024-06-30 | (m) | $-44.84M | (m) |
| 2024-03-31 | (m) | $-49.70M | (m) |
| 2023-12-31 | (m) | $-54.37M | (m) |
| 2023-09-30 | (m) | $-61.63M | (m) |
| 2023-06-30 | (m) | $-53.34M | (m) |
| 2023-03-31 | (m) | $-42.39M | (m) |
| 2022-12-31 | (m) | $-34.68M | (m) |
| 2022-09-30 | (m) | $-85.38M | (m) |
| 2022-06-30 | (m) | $-90.17M | (m) |
| 2022-03-31 | (m) | $-95.24M | (m) |
| 2021-12-31 | (m) | $-89.48M | (m) |
| 2021-09-30 | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) |
| 2020-12-31 | (m) | $-32.95M | (m) |
| 2020-09-30 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |